3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Multiple Myeloma
8
Neoplasms
7
Colorectal Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Ovarian Neoplasms
5
Breast Neoplasms
5
Recurrence
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Glioma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Sarcoma
3
Salivary Gland Neoplasms
3
Pheochromocytoma
3
Paraganglioma
3
Neuroendocrine Tumors
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Lung Neoplasms
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
3
Hematologic Neoplasms
3
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has announcements
×
Metastatic Urothelial Cancer
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA